Predicting Relapse after Cessation of Lamivudine Monotherapy for Chronic Hepatitis B Virus Infection

DOI PDF PubMed 被引用文献7件 オープンアクセス

書誌事項

公開日
2004-02-15
DOI
  • 10.1086/380965
公開者
Oxford University Press (OUP)

この論文をさがす

説明

There have been reports of relapse after cessation of lamivudine monotherapy for hepatitis B virus (HBV) infection. The aim of this study was to examine factors that predict posttreatment relapse. Comparison 22 patients who experienced relapse with 11 who did not after cessation of therapy showed that predictive factors for nonrelapse were hepatitis B e antigen seroconversion and duration of undetectable HBV DNA load (0.7 log IU/mL), as determined by HBV real-time detection direct testing. However, 7 of 12 patients with seroconversion experienced relapse after cessation of therapy. Multivariate analysis revealed that the duration of an undetectable HBV DNA load was the only independent predictive factor for nonrelapse (odds ratio, 0.50; 95% confidence interval, 0.27-0.9). More-prolonged lamivudine therapy is required after seroconversion, and persistent duration of an HBV DNA level of0.7 log IU/mL for6 months can more accurately aid in the decision of when to stop lamivudine therapy.

収録刊行物

被引用文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ